Prevalence and Associated Factors of Endometrial Hyperplasia and Endometrial Cancer in Women with Abnormal Uterine Bleeding and Body Mass Index less than 30 kg/m2 at Charoenkrung Pracharak Hospital
Article Sidebar
Main Article Content
Abstract
Objectives: The primary objective was to determine the prevalence and the associated risk factors of endometrial hyperplasia and endometrial cancer in women with abnormal uterine bleeding (AUB) and body mass index (BMI) less than 30 kg/m2
Materials and Methods: A cross-sectional retrospective study was conducted. The medical records of women with AUB and BMI less than 30 kg/m2 who underwent endometrial sampling or fractional curettage or hysteroscopy with endometrial biopsy from January 1, 2018 to December 31, 2023 were reviewed. The demographic data included age, parity, BMI, menopause, diabetes mellitus, hypertension, tamoxifen used and histopathological reports were collected. The data were analyzed to determine the prevalence of endometrial hyperplasia and endometrial cancer, and multivariate logistic regression were utilized to identify associated risk factors.
Results: Of all 226 women were recruited. The prevalence of endometrial hyperplasia and endometrial cancer was total 9.2%. In multivariate logistic regression analysis, postmenopause (adjusted odds ratio (aOR) 9.39, 95% CI 1.56, 56.71, p = 0.015) and woman older than 60 years old (aOR 12.27, 95% CI 1.93, 78.20, p = 0.008) were independently associated with endometrial hyperplasia and endometrial cancer.
Conclusion: Postmenopause was an important factor for endometrial hyperplasia and endometrial cancer in women with AUB and BMI less than 30 kg/m2, risk increasing significantly in those aged over 60 years. Early detection strategies should be considered.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Jain V, Munro MG, Critchley HOD. Contemporary evaluation of women and girls with abnormal uterine bleeding: FIGO Systems 1 and 2. Int J Gynaecol Obstet 2023;162:29-42.
Zhang CY, Li H, Zhang S, Suharwardy S, Chaturvedi U, Fischer-Colbrie T, et al. Abnormal uterine bleeding patterns determined through menstrual tracking among participants in the Apple Women’s Health Study. Am J Obstet Gynecol 2023;228:213.e1-22.
Narice BF, Delaney B, Dickson JM. Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis. BMC Fam Pract 2018;19:135.
Lacey JV, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009;63:39-44.
Özdemir S, Batmaz G, Ates S, Celik C, Incesu F, Peru C. Relation of metabolic syndrome with endometrial pathologies in patients with abnormal uterine bleeding. Gynecol Endocrinol 2015;31:725-9.
Globocan 2020. Estimated Cancer Incidence and Mortality Thailand in 2020. [Internet]. 2023 [Accessed September 12, 2024]. Available from : http://gco. iarc.fr/
Tangjitgamol S. Endometrial cancer. 1st ed. Bangkok: Faculty of Medicine Vajira Hospital, Navamindradhiraj University; 2016.
Singh G, Cue L, Puckett Y. Endometrial Hyperplasia [Internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan [updated 2024 Apr 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279105/
Sattanakho P, Kleebkaow P, Sangkomkumhang U, Booranabunyat S, Buppasiri P. Rate of significant endometrial pathology in women at low risk for endometrial hyperplasia or cancer presenting with abnormal uterine bleeding. J Minim Invasive Gynecol 2020;27:720-5.
Gawron I, Łoboda M, Babczyk D, Ludwin I, Basta P, Pitynski K, Ludwin A. Endometrial cancer and hyperplasia rate in women before menopause with abnormal uterine bleeding undergoing endometrial sampling. Przegl Lek 2017;74:139-43.
Suwanwanich M. Relative risk factors of abnormal endometrial pathologies in patients with abnormal uterine bleeding. J Dept Med Serv 2019;44:103-7.
Jha S, Singh A, Sinha HH, Bhadani P, Anant M, Agarwal M. Rate of premalignant and malignant endometrial lesions in “low-risk” premenopausal women with abnormal uterine bleeding undergoing endometrial biopsy. Obstet Gynecol Sci 2021;64: 517-23.
Clarke MA, Long BJ, Sherman ME, Lemens MA, Podratz KC, Hopkins MR, et al. Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. Am J Obstet Gynecol 2020;223:549.e1-13.
Giannella L, Cerami LB, Setti T, Bergamini E, Boselli F. Prediction of endometrial hyperplasia and cancer among premenopausal women with abnormal uterine bleeding. Biomed Res Int 2020;2020:8598152.
Wise MR, Gill P, Lensen S, Thompson JM, Farquhar CM. Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women. Am J Obstet Gynecol 2016;215:598.e1-8.
Chen JY, Kuo SJ, Liaw YP, Avital I, Stojadinovic A, Man YG, et al. Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population-based study. J Cancer 2014;5:151-5.
Dowdy SC, Glaser GE, Lurain JR. Uterine cancer. In: Berek JS, editor. Berek & Novak’s Gynecology. 16th ed. Philadelphia: Wolters Kluwer 2020:2359-444.
Sompratthana T, Pohthipornthawat N, Santibenchakul S, Oranratanaphan S. Prevalence of endometrial cancer in patients with endometrioid intraepithelial neoplasia (EIN) histology. Thai J Obstet Gynaecol 2024;32:400-8.
Suwanwanich M. Risk assessment of endometrial hyperplasia and cancer in premenopausal women with abnormal uterine bleeding. Thai J Obstet Gynaecol 2024;32:149-55.
